MS News That Caught My Eye Last Week: Age and DMTs, Tysabri or Gilenya, Sativex Trial, Ocrevus and Mayzent
Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US This is a major step…
Articles by Ed Tobias
MS News That Caught My Eye Last Week: Biotin, Opicinumab, Myelin, Tele-exercise
MD1003 Fails to Prevent Disability Progression in Progressive MS Patients, Trial Shows This is discouraging news for people taking…
aHSCT Gets a Boost in US With NMSS Recommendations
Is the United States a step closer to approving a form of stem cell transplantation as a treatment for multiple…
MS News That Caught My Eye Last Week: Caregivers, VX-765
Majority of MS Patients in US Report Mistreatment by Caregivers in Survey This is a serious issue, but it’s…
Diagnosing MS During a Pandemic: UK vs. US
Editor’s note: Previously, this piece stated that Dr. Ide Smets theorized a transition to telemedicine as the standard of care…
MS News That Caught My Eye Last Week: Mayzent in the UK, Aubagio and Other DMTs, Unemployment
Mayzent Approved for Active SPMS Patients in England and Wales This is great news for people with MS in…
Disability Employment Awareness Isn’t Enough to Keep You Working
My multiple sclerosis (MS) was diagnosed 40 years ago in August. I never kept my MS a secret, but I…
MS News That Caught My Eye Last Week: Comparing DMTs, Myelin Repair, Hypertension
Gilenya and Tecfidera Similarly Effective at Treating RRMS, Real-world Study Says Gilenya and Tecfidera are both oral disease-modifying therapies.
Could Too Many Tattoos Cause MS Trouble?
Many people with multiple sclerosis (MS) get tattoos. Often it’s a way to deliver a statement about MS to…
MS News That Caught My Eye Last Week: Amalgam Fillings, COVID-19 and MS, Tecfidera Generic
MS Patients Should Avoid ‘Silver’ Tooth Fillings Due to Mercury, FDA Advises Concerns about the possible danger of amalgam…
Is the FDA Changing Course on Amalgam Dental Fillings and MS?
For years, some people have warned of a possible connection between multiple sclerosis (MS) and the amalgam fillings many…
MS News That Caught My Eye Last Week: Global MS Numbers, Pregnancy and MS, ANK-700
MS Prevalence at Over 2.8 Million Worldwide, Update to Atlas Reports With almost 3 million of us around the…
Moving Madness Means MS Stress
We’re moving and I’m stressed. That’s redundant, I know, as moving is simply stress on wheels — which isn’t good…
MS News That Caught My Eye Last Week: Economic Impact Survey, Fatigue, DMTs
National MS Society Launches Survey to Assess Economic Impact of MS We know that managing MS is expensive. It…
MS Digs Deep Into the Wallet, Report Shows
Multiple sclerosis (MS) is expensive. Even with good insurance, those of us living in a country without universal healthcare have…
MS News That Caught My Eye Last Week: COVID-19 Survey, MSVirtual2020, Zeposia, B-cells
COVID-19 Pandemic Had Minimal Emotional Impact in Progressive MS Patients, Survey Finds I beg to differ. I have secondary…
Why a Flu Shot Is More Important Than Ever This Year
Labor Day has come and gone here in the U.S. Now, flu season has arrived in the Northern Hemisphere. This…
Amazon’s Halo Judges Your Stress by Listening to Your Voice
You’re stressed, and Halo may know it. Halo is a new Amazon service the company says can judge how stressed…
MS News That Caught My Eye Last Week: Paramagnetic Lesions, Mavenclad, Relapses in Children, Ocrevus and Rituximab
Paramagnetic Rim Lesions Showing Promise as Diagnostic Marker of MS About a year ago, researchers at the U.S. National…
Could a Justice Department Lawsuit Threaten Copay Assistance Programs?
The U.S. Justice Department has the manufacturer of Copaxone (glatiramer acetate injection) in its crosshairs, and the outcome could…
MS News That Caught My Eye Last Week: Kesimpta, Ocrevus and Chickenpox, Generic Tecfidera, UTIs
FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS The U.S. Food and Drug Administration’s approval of Kesimpta (ofatumumab)…
I Give the L300 Go a Mixed Review
I’ve been walking with the Bioness L300 Go for about eight months, so it’s time to update everyone on…
MS News That Caught My Eye Last Week: Ofatumumab, Aubagio, Oral DMTs, PoNS Device
Ofatumumab Seen as Superior to Aubagio at Lowering Relapse Rates in Phase 3 Trials Ofatumumab is a cancer medication…
Could a Tongue Stimulator Help to Improve Your Walking?
The idea doesn’t seem very appealing to me, but a company is seeking approval from the U.S. Food and Drug…
MS News That Caught My Eye Last Week: Epstein-Barr and Smoking, Infections, Oral DMT Trial, Exercise and the Brain
Smoking and Epstein-Barr Virus Combine to Raise MS Risk, Study Says A number of studies over several years have…
‘Crip Camp’: Disability Looking Me Right in the Eye
In early July, I wrote a column about Disability Pride Month. It’s not for me, I said. I questioned…
MS News That Caught My Eye Last Week: Symptom Progression, Lower Urinary Symptoms, Tysabri, IL-17A Protein Study
Order Seen in Motor Skills Affected by MS, With Walking Taking First Hit Read this headline carefully. It reports…
Lemtrada and COVID-19: To Treat or Not to Treat?
Like others these days, I’m worried about COVID-19. In fact, I’m probably more worried than some. I’m old, I have…
MS News That Caught My Eye Last Week: Ketamine, Arbaclofen ER, Bafiertam, UK Health Services
Ketamine May Help Treat MS-related Fatigue, Small Pilot Trial Suggests I’m tired — I mean really bushed. Today, despite…
My Cocker Spaniel, Joey, Is My MS Pal
Do you ever wake up in the middle of the night thinking strange thoughts about your MS and your dog?…